A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
Saved in:
| Title: | A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors. |
|---|---|
| Authors: | Koyama T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Yonemori K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Sato J; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Katsuya Y; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Okada M; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Yoshida T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Okano F; Toray Industries, Inc., New Frontiers Research Laboratories and New Projects Development Division, Kamakura, Kanagawa, Japan., Yamamoto N; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. nbryamam@ncc.go.jp. |
| Source: | Investigational new drugs [Invest New Drugs] 2026 Apr 14. Date of Electronic Publication: 2026 Apr 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
